MA26426A1 - Procedes et intermediaires pour la preparation de b-lactames monocycliques nouveaux et pour compositions pharmaceutiques les contenant - Google Patents

Procedes et intermediaires pour la preparation de b-lactames monocycliques nouveaux et pour compositions pharmaceutiques les contenant

Info

Publication number
MA26426A1
MA26426A1 MA24565A MA24565A MA26426A1 MA 26426 A1 MA26426 A1 MA 26426A1 MA 24565 A MA24565 A MA 24565A MA 24565 A MA24565 A MA 24565A MA 26426 A1 MA26426 A1 MA 26426A1
Authority
MA
Morocco
Prior art keywords
lactams
intermediates
processes
preparation
pharmaceutical compositions
Prior art date
Application number
MA24565A
Other languages
English (en)
Inventor
Dr Dashyant Dhanak
Dr Deirdre Mary Hickey
Bernadette
Dr Colin Andrew Leach
Mr Colin J Theobald
Dr Robert John Ife
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en
Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en
Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA26426A1 publication Critical patent/MA26426A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA24565A 1996-04-26 1997-04-24 Procedes et intermediaires pour la preparation de b-lactames monocycliques nouveaux et pour compositions pharmaceutiques les contenant MA26426A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9608646.7A GB9608646D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9623756.5A GB9623756D0 (en) 1996-11-15 1996-11-15 Novel compounds
GBGB9625121.0A GB9625121D0 (en) 1996-12-03 1996-12-03 Novel compounds

Publications (1)

Publication Number Publication Date
MA26426A1 true MA26426A1 (fr) 2004-12-20

Family

ID=27268259

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24565A MA26426A1 (fr) 1996-04-26 1997-04-24 Procedes et intermediaires pour la preparation de b-lactames monocycliques nouveaux et pour compositions pharmaceutiques les contenant

Country Status (17)

Country Link
EP (1) EP0915843A1 (fr)
JP (1) JP2000509049A (fr)
AR (1) AR006833A1 (fr)
AU (1) AU2698697A (fr)
BR (1) BR9709196A (fr)
CA (1) CA2252696A1 (fr)
CZ (1) CZ341098A3 (fr)
HU (1) HUP9901359A3 (fr)
ID (1) ID16660A (fr)
IL (1) IL126696A0 (fr)
MA (1) MA26426A1 (fr)
NO (1) NO984939L (fr)
NZ (1) NZ332476A (fr)
PE (1) PE64398A1 (fr)
PL (1) PL329530A1 (fr)
TR (1) TR199802160T2 (fr)
WO (1) WO1997041098A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3546601A (en) 2000-02-16 2001-08-27 Smithkline Beecham Plc Pyrimidine-4-one derivatives as LDL-PLA<sub>2</sub> inhibitors
CA2442219C (fr) 2001-03-28 2007-09-11 Schering Corporation Synthese enantioselective de composes intermediaires d'azetidinone
AU2002308778A1 (en) * 2001-05-25 2002-12-09 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
EP2977452A3 (fr) 2007-05-11 2016-05-25 Thomas Jefferson University Procédés de traitement et de prévention de maladies et de troubles neurodégénératifs
MX2009012197A (es) 2007-05-11 2010-01-15 Univ Pennsylvania Metodos para tratamiento de ulceras en la piel.
MX2013006342A (es) 2010-12-06 2013-08-26 Glaxo Group Ltd Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2).
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
US20140171431A1 (en) 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
WO2013013503A1 (fr) 2011-07-27 2013-01-31 Glaxo Group Limited Composés 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one et utilisation en tant qu'inhibiteurs de lp-pla2
EP2736908A1 (fr) 2011-07-27 2014-06-04 Glaxo Group Limited Composés pyrimidones bicycliques
EP2948456A4 (fr) 2013-01-25 2016-09-14 Glaxosmithkline Ip Dev Ltd Composés de pyrimidone bicycliques utilisés en tant qu'inhibiteurs de lp-pla2
SG11201505520WA (en) 2013-01-25 2015-08-28 Glaxosmithkline Ip Dev Ltd 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS
CN105008365B (zh) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 化合物
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
AU2020379796C1 (en) 2019-11-09 2024-05-02 Shanghai SIMR Biotechnology Co., Ltd Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (fr) * 1991-06-25 1993-01-07 Merck & Co., Inc. Azetidinones substituees utilisees comme agents antiinflammatoires et antidegeneratifs
HUT67341A (en) * 1991-07-23 1995-03-28 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof
MY128261A (en) * 1992-10-27 2007-01-31 Merck Sharp & Dohme New substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1994013636A1 (fr) * 1992-12-17 1994-06-23 Merck & Co., Inc. Nouvelles azetidinones a substitution utilisees comme agents anti-inflammatoires et antidegeneratifs
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
ATE201905T1 (de) * 1993-10-06 2001-06-15 Icos Corp Acethylhydrolase des plättchen aktivierenden faktors
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
CA2208530A1 (fr) * 1994-12-22 1996-06-27 Smithkline Beecham P.L.C. Azetidin-2-ones substituees, destinees au traitement de l'atherosclerose
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
KR19990028630A (ko) * 1995-07-01 1999-04-15 데이비드 로버츠 아테롬성 동맥경화증을 치료하기 위한 아제티디논 유도체
JP2000505063A (ja) * 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物

Also Published As

Publication number Publication date
HUP9901359A2 (hu) 1999-08-30
AR006833A1 (es) 1999-09-29
NO984939L (no) 1998-12-23
BR9709196A (pt) 1999-05-25
IL126696A0 (en) 1999-08-17
CZ341098A3 (cs) 1999-03-17
WO1997041098A1 (fr) 1997-11-06
TR199802160T2 (xx) 1999-04-21
JP2000509049A (ja) 2000-07-18
NO984939D0 (no) 1998-10-23
NZ332476A (en) 2000-06-23
PL329530A1 (en) 1999-03-29
HUP9901359A3 (en) 2000-03-28
ID16660A (id) 1997-10-30
AU2698697A (en) 1997-11-19
EP0915843A1 (fr) 1999-05-19
PE64398A1 (es) 1999-01-06
CA2252696A1 (fr) 1997-11-06

Similar Documents

Publication Publication Date Title
MA26426A1 (fr) Procedes et intermediaires pour la preparation de b-lactames monocycliques nouveaux et pour compositions pharmaceutiques les contenant
MA23632A1 (fr) Procede de preparation de composes nouveaux et de compostions pharmaceutiques les contenant
MA26439A1 (fr) Derives d&#39;indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2740136B1 (fr) Derives d&#39;indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
MA26430A1 (fr) 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
ID18663A (id) Komposisi farmasi berlapis enterik
DZ2358A1 (fr) Amides inhibiteurs de sécrétion de apo b/mtp procédé pour leur préparation et compositions pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26620A1 (fr) Derives bicycliques d&#39;acide hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA26638A1 (fr) Derives d&#39;isothiazole nouveaux, procede pour leur preparation et compoositions pharmaceutiques les contenant
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26443A1 (fr) Aralkyl- et aralkylidene-lactames et -imides heterocycliques, procedes pour leur preparation et compositions pharmaceutiques les contenant
MA26571A1 (fr) Derives d&#39;acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
FR04C0032I2 (fr) Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
DZ2461A1 (fr) Dérivés d&#39;arylkylamines nouveaux et composition pharmaceutiques les contenant.
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26428A1 (fr) Derives d&#39;indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
DZ2699A1 (fr) Dérivés d&#39;érythromycine nouveaux procédé et intermédiaires pour préparation et compositions pharmaceutiques les contenant.
MA26490A1 (fr) Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
MA23922A1 (fr) Procede pour la preparation de nouveaux composes monocycliques de b-lactame et de medicament les contenant
PT83896A (fr) Procede pour la preparation de nouveaux conjuges de la vinblas-tine et de ses derives et de compositions pharmaceutiques les contenant
MA26501A1 (fr) Derives de quinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant